Captrust Financial Advisors Raises Stock Holdings in Sera Prognostics, Inc. (NASDAQ:SERA)

Captrust Financial Advisors boosted its holdings in shares of Sera Prognostics, Inc. (NASDAQ:SERA) by 2.2% in the fourth quarter, Holdings Channel.com reports. The fund owned 487,894 shares of the company’s stock after acquiring an additional 10,673 shares during the quarter. Captrust Financial Advisors’ holdings in Sera Prognostics were worth $3,971,000 at the end of the most recent quarter.

Other hedge funds also recently bought and sold shares of the company. BNP Paribas Financial Markets bought a new stake in shares of Sera Prognostics during the fourth quarter worth $28,000. Price T Rowe Associates Inc. MD bought a new stake in Sera Prognostics during the 4th quarter valued at about $93,000. Walleye Capital LLC purchased a new stake in Sera Prognostics in the 4th quarter valued at about $98,000. Wells Fargo & Company MN grew its stake in Sera Prognostics by 55.2% in the 4th quarter. Wells Fargo & Company MN now owns 13,192 shares of the company’s stock worth $107,000 after acquiring an additional 4,691 shares in the last quarter. Finally, Jane Street Group LLC increased its position in shares of Sera Prognostics by 24.8% during the third quarter. Jane Street Group LLC now owns 14,225 shares of the company’s stock worth $111,000 after acquiring an additional 2,826 shares during the period. Institutional investors own 54.64% of the company’s stock.

Sera Prognostics Stock Performance

Shares of NASDAQ SERA opened at $2.22 on Friday. The stock has a 50 day moving average price of $3.48 and a 200 day moving average price of $5.52. The firm has a market capitalization of $83.61 million, a price-to-earnings ratio of -2.24 and a beta of 0.99. Sera Prognostics, Inc. has a 52-week low of $2.10 and a 52-week high of $9.91.

Sera Prognostics (NASDAQ:SERA) last posted its quarterly earnings results on Wednesday, May 14th. The company reported ($0.20) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.24) by $0.04. The firm had revenue of $0.04 million for the quarter, compared to the consensus estimate of $0.06 million. Analysts forecast that Sera Prognostics, Inc. will post -0.96 earnings per share for the current year.

Sera Prognostics Profile

Sera Prognostics, Inc, a women's health diagnostic company, discovers, develops, and commercializes biomarker tests for improving pregnancy outcomes in the United States. The company develops PreTRM test, a blood-based biomarker test to predict the risk of spontaneous preterm birth in singleton pregnancies.